ABPI Scotland

ABPI Scotland - A blueprint for health

There is a huge opportunity for Scotland to be a leader in data systems and genomic diagnostics, as well as adopting policies that support access to innovation for patients. The extent to which Scotland benefits – and perhaps leads – will ultimately be down to whether policymakers choose to adopt and fully harness the potential of research and innovation in healthcare.

Fraser of Allander Institute - The economic contribution of the Pharmaceuticals Sector in Scotland - February 2023

This report goes beyond economic impact assessment, highlighting the sector’s wider impact on the Scottish economy.

Scottish Cross Party Group Life Sciences Annual Report 2021-2022

The Group acts as a channel for communication and information between the Scottish Parliament and people within organisations working in the life sciences sector in Scotland across industry, academia, research, and manufacturing.

Scottish Cross Party Group Life Sciences Annual Report 2021-2022

The Group acts as a channel for communication and information between the Scottish Parliament and people within organisations working in the life sciences sector in Scotland across industry, academia, research, and manufacturing.

ABPI Scottish Cancer Recovery Roundtable

The COVID-19 pandemic has brought challenges to the way cancer treatments and clinical trials are delivered across Scotland and it is clear that collaboration will be required to ensure care returns to pre-pandemic levels.

ABPI Scotland 2021 Manifesto for Medicine

Our manifesto outlining a number of actions for the next Scottish Government to take that will improve the nation’s collective health and wealth.

The economic contribution of the pharmaceutical sector in Scotland

The pharmaceutical sector plays an important role in the Scottish economy. This report, by the Fraser of Allander Institute (FAI) at the University of Strathclyde, looks at the value of the sector.

The economic contribution of the pharmaceutical industry in Scotland

This analysis has been prepared by the Fraser of Allander Institute (FAI) at the University of Strathclyde. The technical analysis, methodology and writing of the results was undertaken independently by the FAI. It explores the value of the pharmaceutical industry in Scotland.

ABPI Scotland: Medicines for Scottish life

Health outcomes in Scotland are improving. Cancer survival, for instance – which is heavily dependent on oncology medicines – has improved by 18 per cent for men and 15 per cent for women between 1983 and 2007.

Contribution of pharma-related businesses to the Scottish economy

This is the third in a series of independent reports commissioned by ABPI Scotland with Ewen Peters’ Associates (EPA) which estimates the economic impact of “pharma-related businesses” in Scotland, both directly and more widely.

Report of a survey of service provision for patients with RA and associated conditions

This is the report of a survey of service provision, and the opinions of those delivering services, for patients with RA and associated conditions. It is a snapshot of this area of patient care that is felt by many of those involved to have a lower priority in terms of policy and resources than it should.

The future burden of CHD and diabetes in Scotland: The value of healthcare innovation

2005 report says NHS Scotland could save thousands of lives, avoid 80,000 bed days and more efficiently use health resources. Health innovation has an important part to play in managing the burden of diabetes and CHD in Scotland; saving and improving the quality of patients lives, according to an economic report published in 2005.